#United States #New York #Karyopharm #XPOVIO #cancer therapies

Karyopharm Therapeutics at the Piper Sandler Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a pioneering company in the field of novel cancer therapies, has confirmed its participation in the Piper Sandler 36th Annual Healthcare Conference. The event, which promises to gather industry leaders and innovators, is scheduled for December 3, 2024, in New York City.

Event Details

The senior management team of Karyopharm is set to engage in a dynamic fireside chat at 11:30 a.m. ET during the conference. This chat will provide insights into Karyopharm's latest advancements and strategic vision in combatting cancer.

For those unable to attend in person, a live webcast of the discussion will be accessible through the company's investor relations page, Karyopharm Events & Presentations. Following the event, the recording will also be available for replay, ensuring that all interested parties can benefit from the valuable information shared during the session.

About Karyopharm Therapeutics

Founded with a mission to transform the treatment landscape for cancer patients, Karyopharm Therapeutics is recognized for its innovative approaches to combatting various malignancies. The company has established itself as a leader in developing oral compounds that specifically target nuclear export dysregulation, a critical factor in the development of cancers.

XPOVIO®: A Breakthrough in Treatment

At the forefront of Karyopharm's offerings is XPOVIO® (selinexor), an exportin 1 (XPO1) inhibitor that holds the distinction of being in a class of its own. This groundbreaking treatment is not only approved in the United States for multiple oncology indications but is also marketed internationally under the variant NEXPOVIO® in Europe and the UK, and has gained traction in markets like China.

Karyopharm's robust pipeline continues to address several critical cancer types, including but not limited to multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). The company focuses on areas with high unmet medical needs to improve patient outcomes and deliver hope for those battling cancer.

Commitment to Patient-Centric Innovation

Karyopharm’s innovation extends beyond product development. The company believes in the resilience and bravery of cancer patients, driving a culture that emphasizes compassion and a strong commitment to scientific advancement. The participation in events like the Piper Sandler conference showcases Karyopharm's dedication to remaining at the forefront of cancer therapeutics while connecting with fellow leaders and stakeholders in the healthcare industry.

For more information about Karyopharm, its people, science, and pipeline, you can visit Karyopharm’s official website and follow them on LinkedIn and X @Karyopharm.

Conclusion

Karyopharm Therapeutics is set to make waves at the upcoming Piper Sandler Healthcare Conference, providing insights into its innovative approaches to cancer treatment. Stay tuned for exciting updates as the company continues to lead with compassion and cutting-edge science in the fight against cancer.